IL6 and breast cancer: TNBC cells expressing oncogenic multiple copies in T cell malignancy 1 (MCT-1) induces IL-6 via IL-6R and promotes macrophage polarization into M2-like macrophages while silencing MCT-1 and blocking IL-6R by tocilizumab, reducing IL-6R expression and macrophage polarization in breast cancer [174].